Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion

Clinical Endocrinology

Volumn 50, Issue 2, 1999, Pages 245-251

  Hunter, S J ^a   Shaw, J A M ^b   Lee, K O ^c   Wood, P J ^d   Atkinson, A B ^a   Bevan, J S ^b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GROWTH HORMONE RELEASE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSSPHENOIDAL SURGERY;

ACROMEGALY; ADULT; BIOLOGICAL MARKERS; DELAYED-ACTION PREPARATIONS; FEMALE; GROWTH HORMONE; HORMONES; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; REGRESSION ANALYSIS;

EID: 0005995999     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.1999.00668.x     Document Type: Article

References (28)

1. Alexander, L., Appleton, D., Hall, R., Ross, W.M. & Wilkinson, R. (1980) Epidemiology of acromegaly in the Newcastle region. Clinical Endocrinology, 12, 71-79.
2. Argente, J., Caballo, N., Barrios, V., Muroz, M.T., Pozo, J., Chowen, J.A., Morande, G. & Hernandez, M. (1997) Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in patients with anorexia nervosa: effect of short- and long-term weight recuperation. Journal of Clinical Endocrinology and Metabolism, 82, 2084-2092.
3. Bates, A.S., van't Hoff, W., Jones, J.M. & Clayton, R.N. (1993) An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine, 86, 293-299.
4. Bates, A.S., Evans, A.J., Jones, P. & Clayton, R.N. (1995) Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clinical Endocrinology, 42, 417-423.
5. Bengtsson, B., Staffan, E., Ingrid, E., Anders, O. & Bjorn, S. (1988) Epidemiology and tong-term survival in acromegaly. Acta Medica Scandinavica, 223, 327-335.
6. Blum, W.F. & Ranke, M.B. (1990a) Use of insulin-like growth factor-binding protein 3 for the evaluation of growth disorders. Hormone Research, 33(Suppl 4), 31-37.
7. Blum, W.F. & Ranke, M.B. (1990b) Insulin-like growth factor binding proteins (IGFBPs) with special reference to IGFBP-3. Acta Paediatric Scandinavica, 367(Suppl), 55-62.
8. Chiodini, P.G., Cozzi, R., Dallabonzana, D., Oppizzi, G., Verde, G., Petroncini, M., Liuzzi, A. & Del Pozo, E. (1987) Medical treatment of acromegaly with SMS 201-995, a somatostatin analogue: a comparison with bromocriptine. Journal of Clinical Endocrinology and Metabolism, 64, 477-453.
9. Christensen, S.E., Week, J., Orskov, H., Moller, N., Flyvbjerg, A., Harris, A.G., Lund, E. & Jorgensen, J. (1987) Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clinical Endocrinolgy, 29, 297-306.
10. Ciccarelli, F., Miola, C., Grottoli, S., Avataneo, T., Lancranjan, I. & Camanni, F., (1993) Long-term therapy of patients with macro-prolactinoma using repeatable injectable bromocriptine. Journal of Clinical Endocrinology and Metabolism, 76, 484-488.
11. Clayton, R.N. (1993) Modern management of acromegaly. Quarterly Journal of Medicine, 86(5), 285-287.
12. Dobrashian, R.D., O'Halloran, D.J., Hunt, A., Beardwell, C.G. & Shalet, S.M. (1993) Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly. Clinical Endocrinology, 38, 589-593.
13. Flogstad, A.K., Halse, J., Haldorsen, T., Lancranjan, I., Marbach, P., Bruns, C.H. & Jewell, J. (1995) Sandostatin LAR in acromegalic patients: a dose-range study. Journal of Clinical Endocrinology and Metabolism, 80, 3601-3607.
14. Flogstad, A.K., Halse, J., Bakke, S., Lancranjan, I., Marbach, P., Bruns, C.H. & Jewell, J. (1997) Sandostatin LAR in acromegalic patients: long term treatment. Journal of Clinical Endocrinology and Metabolism, 82, 23-28.
15. Grinspoon, S., Clemmons, D., Swearingen, B. & Klibanski, A. (1995) Serum insulin-like growth factor - binding protein -3 levels in the diagnosis of acromegaly. Journal of Clinical Endocrinology and Metabolism, 80, 927-932.
16. Hartman, M.L., Veldhuis, J.D., Vance, M.L., Faria, A.C.S., Furlanetto, R.W. & Thorner, M.O. (1990) Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. Journal of Clinical Endocrinology and Metabolism, 70, 1375-1384.
17. Jorgensen, J.O.L., Moler, N., Moller, J., Weeke, J. & Blum, W.F. (1994) Insulin like growth factors (IGF)-I and II and IGF binding protein-1-2 and -3 in patients with acromegaly before and after adenomectomy. Metabolism, 43, 579-583.
18. Juul, A., Main, K., Blum, W.F., Lindholm, J., Rauke, M.B. & Skakkebaek, N.E. (1994) The ratio between serum levels of insulin-like growth factor (IGF-)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clinical Endocrinology, 41, 85-93.
19. Lee, K.O., Oh, Y., Giudice, L.C., Cohen, P., Peehl, D.M. & Rosenfeld, R.G. (1994) Identification of insulin-like growth factor-binding protein-3 (IGFBP-3) fragments and IGFBP-5 proteolytic activity in human seminal plasma. Journal of Clinical Endocrinology and Metabolism, 79, 1367-1372.
20. Macleod, A.F., Clarke, D.G., Pamhakian, H., Lowy, C., Sonksen, P.H. & Collins, P.D. (1989) Treatment of acromegaly by external irradiation. Clinical Endocrinology, 30, 303-314.
21. McKnight, J.A., McCance, D.R., Crothers, J.G. & Atkinson, A.B. (1989) Changes of glucose tolerance and development of gallstones during high dose somatostatin analogue therapy (SMS 201-995 octreotide) for acromegaly. British Medical Journal, 299, 604-605.
22. McKnight, J.A., McCance, D.R., Sheridan, B., McIlrath, E., Hadden, D.R., Kennedy, L. & Atkinson, A.B. (1991) A long term dose-response study of somatostatin analogue (SMS 201-995 octreotide) in resistant acromegaly. Clinical Endocrinology, 34, 119-125.
23. Melmed, S., Ho, K., Klibanski, A., Reichlin, S. & Thorner, M. (1995) Recent advances in pathogenesis diagnosis and management of acromegaly. Journal of Clinical Endocrinology and Metabolism, 80, 3395-3402.
24. Newman, C.B., Melmed, S., Snyder, P.J., Young, W.F., Boyajy, L.D., Levy, R., Stewart, W.N., Klibanski, A., Molitch, M.E. & Gagel, R.F. (1995) Safety and efficacy of long term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients. - A clinical research center study. Journal of Clinical Endocrinology and Metabolism, 80, 2768-2775.
25. Rajasoorya, C., Holdaway, I.M., Wrightson, P., Scott, D.J. & Ibbertson, H.K. (1994) Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology, 41, 95-102.
26. Shimatsu, A., Nakamura, Y., Ihara, C., Mizuta, H. & Murabe, H. (1996) Serum insulin-like growth factor-II (IGF-II) levels in patients with acromegaly and growth hormone deficiency: correlation with IGF-I and IGF binding protein-3. Endocrine Journal, 43, S71-S73.
27. Stewart, P.M., Kane, F.K., Stewart, S.E., Lancranjan, I. & Sheppard, M.C. (1995) Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. Journal of Clinical Endocrinology and Metabolism, 80, 3267-3272.
28. Tauber, J.P., Babin, T., Tauber, M.T., Vigoni, F., Bonafe, A., Ducasse, M., Harris, A.G. & Bayard, F. (1989) Long term effects of continuous subcutaneous infusion of somatostatin analog octreotide in the treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism, 68, 917-924.